BAR­DA looks to get the jump on next pan­dem­ic with VC arm tar­get­ing 'trans­for­ma­tive' tech

Five years af­ter Con­gress first called for it — and a year and a half af­ter a pan­dem­ic broke out — BAR­DA, the US’s top pan­dem­ic pre­pared­ness agency, is launch­ing its own VC fund.

The new fund will in­vest in tech­nolo­gies that could be de­ployed against fu­ture out­breaks or oth­er pub­lic health emer­gen­cies. It fol­lows a sim­i­lar mod­el to oth­er pub­lic health VCs, such as the Gates Foun­da­tion’s fund, giv­ing cap­i­tal to ear­ly-stage com­pa­nies with promis­ing plat­form tech­nolo­gies in ex­change for as­sur­ances they use it part­ly for in­fec­tious dis­eases that might not have a sig­nif­i­cant mar­ket.

Sandeep Pa­tel

Sandeep Pa­tel, di­rec­tor of BAR­DA’s di­vi­sion of Re­search, In­no­va­tion and Ven­tures, name-checked mR­NA vac­cines, a tech­nol­o­gy that was be­ing de­vel­oped in large part for can­cer be­fore Covid-19, but which an­oth­er branch of the gov­ern­ment — DARPA — in­vest­ed in as a pan­dem­ic pre­pared­ness tool.

It’s “look­ing at what’s po­ten­tial­ly trans­for­ma­tive,”  he told End­points News. “mR­NA rep­re­sent­ed a kind of new class of vac­cines. What’s the equiv­a­lent of that we can in­vest in for the fu­ture, ei­ther in vac­cines, treat­ments or di­ag­nos­tics? Or even things that cut across those ar­eas.”

Fit­ting­ly for a long-over­looked gov­ern­ment agency de­pen­dent on Con­gress for cash, the fund is for now mod­est. BAR­DA has com­mit­ted on­ly $10 mil­lion this year and $50 mil­lion over the next five years to the VC, al­though Pa­tel said that they hope to raise that up to $500 mil­lion over the next decade. He not­ed that Pres­i­dent Joe Biden’s new bud­get in­cludes $50 mil­lion for year one of the ef­fort, should it be passed.

They al­so plan to match their own in­vest­ments with pri­vate cap­i­tal. Con­gress au­tho­rized the VC fund in 2016 as part of the 21st Cen­tu­ry Cures Act, but Pa­tel said they need­ed time to fig­ure out its mod­el. Af­ter so­lic­it­ing bids in the fall, the agency an­nounced it will team with GHIC, a Gates-fund­ed non-prof­it that will look to mar­shal more con­ven­tion­al VCs to bur­nish BAR­DA’s ef­forts.

De­spite its pre-pan­dem­ic his­to­ry, the new fund fits in­to a broad­er push to de­vel­op tech­nolo­gies, in­fra­struc­ture and oth­er ca­pa­bil­i­ties to pre­vent the next pan­dem­ic, join­ing gov­ern­ment and aca­d­e­m­ic ef­forts to de­vel­op pan-vi­ral vac­cines and in­dus­try ef­forts to reimag­ine bi­o­log­ics man­u­fac­tur­ing, so any fu­ture pan­dem­ic vac­cine or treat­ment could be rapid­ly scaled.

It’s a de­par­ture from where BAR­DA has spent much of the funds in the past, when it di­rect­ed tens of mil­lions of dol­lars to get in­di­vid­ual prod­ucts — of­ten an­tibi­otics with­out an im­me­di­ate com­mer­cial mar­ket — through late-stage stud­ies.

Pa­tel said they’ll in­vest in com­pa­nies — around five to nine per year — that have clear­er com­mer­cial ap­pli­ca­tions out­side of pub­lic health emer­gen­cies, so it will be sus­tain­able with­out heavy pub­lic fund­ing and ready if a cri­sis strikes. As with oth­er non-prof­it ven­ture ef­forts, any re­turns from those in­vest­ments would be fun­neled back in­to the fund to be re-in­vest­ed. He com­pared it to In-Q-Tel, the CIA’s VC arm.

What could those tech­nolo­gies or com­pa­nies be? Pa­tel wouldn’t dive in­to too many specifics, but he threw out nee­dle-free vac­cines, which BAR­DA has al­ready mod­est­ly in­vest­ed in,  and new meth­ods for rapid­ly scal­ing man­u­fac­tur­ing — any­thing that could turned around faster for Covid-28, or what­ev­er strikes next.

“There’s a lot, there’s a long list here, we’re in the process of set­ting pri­or­i­ties,” Pa­tel said. “Clear­ly Covid-19 has showed us some lessons”

So­cial im­age: Rick Bright (Pho­to by Greg Nash / POOL / AFP) (Pho­to by GREG NASH/POOL/AFP via Get­ty Im­ages)

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

The dynamic in the biotech market has been highly volatile in the last few years, from the high peaks immediately after the COVID vaccine in 2021, to the lowest downturns of the last 20 years in 2022. This uncertainty makes calling the exact timing of the market’s turn something of a fool’s errand, according to Dr. Chen Yu, Founder and Managing Partner of TCG Crossover (TCG X). He speaks with RBC’s Noël Brown, Head of US Biotechnology Investment Banking, about the market’s road ahead and two possible paths for growth.

Vlad Coric, Biohaven CEO

Vlad Coric charts course for new Bio­haven with neu­ro­science push and Big Phar­ma vets on board

What’s Biohaven without its CGRP portfolio? That’s what CEO Vlad Coric is tasked with deciding as he maps out the new Biohaven post-Pfizer takeover.

Pfizer officially scooped up Biohaven’s CGRP assets on Monday, including blockbuster migraine drug Nurtec and the investigational zavegepant, for $11.6 billion. As a result, Coric spun the broader pipeline into an independent company on Tuesday — with the same R&D team behind Nurtec but about 1,000 fewer staffers and a renewed focus on neuroscience and rare disease.

In AstraZeneca's latest campaign, wild eosinophils called Phils personify the acting up often seen in uncontrolled asthma

As­traZeneca de­buts an­noy­ing pur­ple ‘Phil’ crea­tures, per­son­i­fied asth­ma eosinophils ‘be­hav­ing bad­ly’

There are some odd-looking purple creatures lurking around the halls of AstraZenca lately. The “Phil” character cutouts are purple, personified eosinophils with big buggy eyes and wide mouths, and they’re a part of AZ’s newest awareness effort to help people understand eosinophilic asthma.

The “Asthma Behaving Badly” characters aren’t only on the walls at AZ to show the new campaign to employees, however. The “Phils” are also showing up online on the campaign website, and in digital and social ads and posts on Facebook and Instagram.

Casey McPherson shows his daughters Rose (left) and Weston around Everlum Bio, a lab that he co-founded to spark a treatment for Rose and others with ultra-rare conditions. (Ilana Panich-Linsman)

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Under bright lab lights, Casey McPherson holds his 6-year-old daughter, Rose. His free hand directs Rose’s gaze toward a computer screen with potential clues in treating her one-of-a kind genetic condition.

Gray specks on the screen show her cells that scientists reprogrammed with the goal of zeroing in on a custom medicine. McPherson co-founded the lab, Everlum Bio, to spark a treatment for Rose — and others like her. A regarded singer-songwriter, McPherson never imagined going into drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Christophe Bourdon, Leo Pharma CEO

Leo Phar­ma looks 'be­yond the skin' in atopic der­mati­tis aware­ness cam­paign

As Leo Pharma aims to take on heavyweight champ Dupixent in atopic dermatitis, the company is launching “AD Days Around the World,” an awareness campaign documenting real patient stories across Europe.

The project, unveiled on Monday, spotlights four patients: Marjolaine, Laura, Julia and África from France, Italy, Germany and Spain, respectively, in short video clips on the challenges of living with AD, the most common form of eczema.

Ying Huang, Legend CEO

Lentivi­ral vec­tor ramp-up: J&J and Leg­end to in­vest $500M in New Jer­sey man­u­fac­tur­ing to sup­port Carvyk­ti

In response to a question on manufacturing scale at Legend Biotech’s R&D day yesterday, the company’s top exec said its partnership with Johnson & Johnson will be doubling its investment in its New Jersey manufacturing center and will be investing a total of $500 million.

With an eye on their BCMA-directed CAR-T therapy Carvykti (cilta-cel), approved in February as a fifth-line treatment for multiple myeloma, Legend CEO Ying Huang said that the ramp-up in production and the decision to manufacture its own lentiviral vectors — currently in shortage worldwide — means they won’t have to deal with that shortage.

Kite Phar­ma gets FDA to sign off on new Cal­i­for­nia-based vec­tor man­u­fac­tur­ing fa­cil­i­ty

Kite Pharma just got FDA approval to kick off operations at a new manufacturing campus.

The cancer-focused, CAR-T cell therapy player made the announcement Monday, saying that the federal regulatory agency gave the green light to Kite’s 100,000 square-foot, retroviral vector manufacturing facility in Oceanside, CA.

Kite’s global head of technical operations Chris McDonald tells Endpoints News that the facility has been in the works for about four years, after Kite teamed up with its parent company Gilead. Gilead acquired Kite Pharma for just shy of $12 billion in 2017.

Mar­ket­ingRx roundup: No­var­tis re­cruits NFL coach for Leqvio cam­paign; Pfiz­er pro­motes ‘Sci­ence’ merch on so­cial me­dia

Novartis is turning to a winning coach to talk about Leqvio and the struggles of high cholesterol — including his own. Bruce Arians, the retired NFL head coach of the Arizona Cardinals and Super Bowl-winning Tampa Bay Buccaneers, is partnering with the pharma for its “Coaching Cholesterol” digital, social and public relations effort.

In the campaign, Arians talks about the potential for “great comebacks” in football and heart health. Once nicknamed a “quarterback whisperer,” he is now retired from fulltime coaching (although still a front-office consultant for Tampa Bay), and did a round of media interviews for Novartis, including one with People and Forbes.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Amy West, Novo Nordisk head of US digital innovation and transformation (Illustration: Assistant Editor Kathy Wong for Endpoints News)

Q&A: No­vo Nordisk dig­i­tal in­no­va­tion chief Amy West dis­cuss­es phar­ma pain points and a health­care 'easy but­ton’

Amy West joined Novo Nordisk more than a decade ago to oversee marketing strategies and campaigns for its US diabetes portfolio. However, her career path shifted into digital, and she hasn’t looked back. West went from leading Novo’s first digital health strategy in the US to now heading up digital innovation and transformation.

She’s currently leading the charge at Novo Nordisk to not only go beyond the pill with digital marketing and health tech, but also test, pilot and develop groundbreaking new strategies needed in today’s consumerized healthcare world.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.